56 studies found for:    Open Studies | "Unrelated Donors"
Show Display Options
Rank Status Study
21 Recruiting TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
Conditions: Primary Immune Deficiency Disorder;   Hematopoietic Stem Cell Transplantation
Intervention: Other: Biological: TCR alfa beta T cell depletion
22 Recruiting Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
Condition: DOCK8 Deficiency
Interventions: Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Equine ATG;   Drug: Busulfan (Busulfex)
23 Recruiting Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
Conditions: Leukemia;   Inborn Errors of Metabolism;   Bone Marrow Failure Syndromes;   Immunodeficiencies;   Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
Intervention: Device: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
24 Recruiting Infusion of Depleted T Cells Following Transplant in Adults With Acute Leukaemia (ICAT)
Condition: Haematological Malignancies
Intervention: Biological: CD25/71 allodepleted donor T-cells
25 Recruiting Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
Condition: Anemia, Aplastic
Intervention: Drug: Cyclophosphamide,Campath IH and TBI
26 Recruiting Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
Conditions: Graft vs Host Disease;   Hematologic Neoplasms;   Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions: Drug: Vorinostat;   Drug: Tacrolimus;   Drug: Methotrexate
27 Unknown  Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Condition: Hematopoietic/Lymphoid Cancer
Interventions: Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
28 Unknown  Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute Graft Versus Host Disease (aGVHD) During Transplant
Conditions: AML;   ALL;   Undifferentiated Leukemia;   Biphenotypic Leukemia;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts;   Refractory Anemia With Excess Blasts-1 (5-10% Blasts);   Refractory Anemia With Excess Blasts-2 (10-20% Blasts);   Myelodysplastic Syndrome, Unclassified;   MDS Associated With Isolated Del (5q)
Intervention: Drug: Abatacept
29 Recruiting Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Condition: Inherited Immune Deficiencies
Interventions: Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
30 Unknown  Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation
Condition: Hematologic Malignancies
Interventions: Biological: Anti-Thymocyte Globulin (Rabbit);   Other: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)
31 Recruiting Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases
Conditions: Bone Marrow Failure Syndromes;   Immunodeficiencies;   Immune Dysregulation Syndromes
Intervention: Device: CD3+/CD19+ delpletion using CliniMACs device follwing reduced intensity conditioning
32 Recruiting Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Other: pharmacological study
33 Recruiting Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression
Condition: Graft Versus Host Disease
Intervention: Drug: Tacrolimus and MMF.
34 Unknown  Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: methotrexate;   Procedure: allogeneic hematopoietic stem cell transplantation
35 Recruiting Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   T-Cell Large Granular Lymphocyte Leukemia
Interventions: Drug: Fludarabine Phosphate;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
36 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
37 Recruiting HCT Versus CT in Elderly AML
Condition: Acute Myeloid Leukemia
Interventions: Procedure: hematopoietic cell transplantation;   Drug: Non-Transplant treatment approach for consolidation
38 Recruiting Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
Conditions: Leukemia;   Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Severe Aplastic Anemia;   Allogeneic Transplant
Intervention: Drug: Cyclophosphamide
39 Recruiting Phase II Maraviroc for GVHD Prevention
Condition: Hematologic Malignancy Requiring Allogeneic Stem-cell Transplantation.
Intervention: Drug: Maraviroc 300 mg
40 Recruiting Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Conditions: Blood Stem Cell Transplant Failure;   Leukemia;   Hematologic Malignancies
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Procedure: Stem Cell Transplantation;   Drug: Thiotepa;   Drug: Tacrolimus;   Drug: Mycofenolate mofetil;   Drug: G-CSF

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-56) Show next page of results    Last Page
Indicates status has not been verified in more than two years